Fresenius SE & Co KGaA (FRE) Receives Average Recommendation of “Buy” from Brokerages

Shares of Fresenius SE & Co KGaA (FRA:FRE) have been given a consensus rating of “Buy” by the twenty ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is €78.16 ($96.50).

A number of brokerages have recently issued reports on FRE. Societe Generale set a €85.00 ($104.94) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Monday, March 5th. Berenberg Bank set a €89.10 ($110.00) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Tuesday, March 6th. Goldman Sachs Group set a €71.00 ($87.65) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Tuesday, February 27th. Barclays set a €81.00 ($100.00) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Friday. Finally, Kepler Capital Markets set a €63.00 ($77.78) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Tuesday, February 27th.

How to Become a New Pot Stock Millionaire

Shares of Fresenius SE & Co KGaA (FRE) traded down €0.22 ($0.27) during midday trading on Wednesday, hitting €65.68 ($81.09). 720,647 shares of the stock were exchanged. The stock has a market cap of $36,310.00 and a P/E ratio of 21.39. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($74.27) and a 12-month high of €80.00 ($98.77).

WARNING: “Fresenius SE & Co KGaA (FRE) Receives Average Recommendation of “Buy” from Brokerages” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/03/12/fresenius-se-co-kgaa-fre-receives-average-recommendation-of-buy-from-brokerages.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply